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Abstract  200 Words, max 200 
Background:  
The restrictions introduced in response to COVID-19 present many challenges, particularly for 
vulnerable and marginalised populations. These include maintaining access to Needle and Syringe 
Programmes (NSPs) to reduce the harms associated with injecting drugs. NSPs effectiveness is 
coverage dependent, but lockdowns and social distancing limit NSP access and availability. The 
impact on NSP provision in England is explored using enhanced monitoring data.  
Method:  
Data collected through an established comprehensive monitoring system from five four-week 
periods, centred on the implementation of restrictions in the UK in mid-March 2020, are examined. 
Weekly averages are compared to allow for public holidays and weekly variation in activity. 
Results:  
The restrictions resulted in the number of NSP clients decreasing by 36%, visits by 36%, and needles 
distributed by 29%. NSP coverage for those injecting psychoactive drugs halved, declining from 14 
needles per-week during the 4-weeks to 15th March 2020 to 7 needles per-week by mid-April, and 
coverage has remained at this level since then. 
Conclusions:  
Though it is currently unclear if there has been a decline in injecting, the decline in NSP coverage is 
so marked that it almost certainly reflects decreased utilisation among those in need, indicating 
increased equipment reuse and risk. 




The current novel coronavirus (COVID-19) pandemic presents many challenges, the impacts of which 
are particularly experienced by vulnerable and marginalised populations, including those who use 
drugs (Marsden, et al., 2020). One of these challenges is maintaining safe injection practice through 
the sufficient provision of sterile needles and syringes to people who inject drugs (Bartholomew, 
Nakamura, Metsch, & Tookes, 2020).  
Needle and Syringe Programmes (NSP) are key to preventing and controlling many of the harms 
associated with injecting drug use, such as HIV, hepatitis C (HCV) and skin and soft tissue infections 
(SSTIs)(ECDC & EMCDDA, 2011). Evidence indicates that, when delivered with sufficient coverage 
and in parallel with other interventions, such as opioid substitution therapy, they have a core role to 
play in the elimination of HCV (Turner, et al., 2011; Ward, et al., 2018) and minimising other harms. 
Delivering NSP to people who inject drugs with sufficient coverage is challenging under normal 
circumstances (EMCDDA, 2019; Larney, et al., 2017); the social distancing measures introduced in 
response to COVID-19 make this even harder (Bartholomew, et al., 2020).   
NSPs aim to provide clean injecting equipment and advice in order to minimise the sharing of 
injecting equipment and improve injecting hygiene, and so reduce the risk of blood-borne viral 
infections, SSTIs and other harms, such as overdose (Jones, Pickering, Sumnall, McVeigh, & Bellis, 
2010; NICE, 2014). To be effective they should be available in settings that are easy for people who 
use drugs to access, with NSP provided through specialist services, mobile units, community 
pharmacies, vending machines and emergency departments. In the UK NSP provision is widespread, 
with the predominant mode of delivery being community pharmacies, though provision through 
stand-alone specialist services for people who use drugs is also common (NICE, 2014). 
In March 2020 the UK Government introduced restrictions in response to COVID-19, the 
implementation of which started during the week commencing the 16th March ("PM statement on 
coronavirus: 16 March," 2020), and these were fully implemented during following week. The 
restrictions required people to stay at home, with the exception of essential journeys (i.e. food 
shopping, daily exercise, for healthcare, or to go to work if a key worker), and to follow social 
distance guidelines which included maintaining a 2 metre distance from people outside their 
household when not at home (PHE, 2010; "PM address to the nation on coronavirus: 23 March," 
2020; "PM statement on coronavirus: 16 March," 2020). Other measures implemented included 
housing people living on the streets in hotels and other accommodation (MHCLG, 2020). 
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To inform actions to limit the negative impacts of the COVID-19 restriction on people who inject 
drugs, the data set collected by an established regional monitoring system in the North West of 
England (IMS, 2020) was expanded. Enhanced data from this system was fed back directly to those 
commissioning services weekly, and fed into COVID-19 response systems including local authority 
led local resilience forums and regional meetings of the Commissioners and Providers of services for 
people who use drugs. The impact of the restrictions on NSPs in England are assessed using this 
data. Changes in the utilisation and coverage of NSP are examined over the 20-week period centred 
around the implementation of the COVID-19 restrictions. 
Method 
The Integrated Monitoring System (IMS) is an established system for monitoring the provision of low 
threshold interventions, including NSP, across Cheshire and Merseyside (pop 2,482,336), in the 
North West of England (IMS, 2020). The system collects NSP activity data from nine local authorities, 
where NSP are provided through either community pharmacies or by specialist services. In January 
2020, there were 92 community pharmacies and 25 specialist service sites providing NSP. 
Data collection was enhanced in response to COVID-19 to inform mitigation of the impacts of 
restrictions imposed. This enhancement had two components. Firstly, additional data collection was 
established to monitor the accessibility of services; collecting data on whether sites were still 
providing NSP, opening hours and access restrictions. The existing data collection was also enhanced 
to collate and report weekly activity where possible, with data obtained via weekly extracts provided 
directly by the specialist services, and through two software packages used by pharmacies. Data was 
returned each Monday on activity recorded up to the preceding day. An extract of all quarterly 
activity was provided each week to permit updates to account for any lags in entering data. Data on 
number of NSP visits (transactions), client numbers and amount of equipment are available by main 
type of substance used (psychoactive or image and performance enhancing [IPED]).  
Changes in NSP activity over time were examined using five 4-week periods, with the base period 
being the four weeks ending the 15th March 2020 (i.e. the period just before implementation of the 
restrictions). Changes in number of clients, visits and needles distributed over time are examined 
using weekly averages. Weekly averages are used as activity fluctuates from week-to-week, 
reflecting that some individuals do not collect equipment every week and this can be further 
impacted by public and other holidays. Data was examined overall and by drug type (psychoactive or 
image and performance enhancing). Number of clients and visit during 2020 were also compared 
with comparable 4-week periods in 2019. Finally, using the most recent published estimates the size 
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of the population injecting opiates and/or crack, the most commonly injected psychoactive drugs in 
England (Hay, Rael dos Santos, & Millar, 2013), the impact on NSP coverage was assessed.  
Results 
In April 2020, 105 (91%) of the 115 sites providing NSP services that could be contacted remained 
open with social distancing measures in place. Of these sites, 45% had reduced hours or had 
additional access restriction in place (such as queuing systems). Service also reported adopting new 
approaches to providing NSP to people resident in hostels in response to social distancing and the 
measures introduced to house those living on the streets. 
Monitoring of NSP activity data shows that the number of clients, visits, and number of needles all 
dropped substantially from mid-March 2020, see figure. In the 4-week period ending 12th April these 
were down by 36% (from a mean of 662 clients per week to 426), 36% (from a mean of 1,424 visits 
per week to 913), and 29% (from a mean of 59,026 needles per week to 41,772) respectively when 
compared to the 4-week period ending 15th March 2020. The impact was greatest on people 
attending because of IPED use; for example, mean number of clients reporting IPED use per week 
was down by 52% (232 to 111), whereas the number of clients using psychoactive drugs was down 
by only 27% (430 to 316).  
In the period prior to 16th March 2020 the average number of clients and visit were slightly higher 
than in the same period during 2019 (number of clients by 8% and number of visits by 6%, see 
figure). Since 16th March 2020, these have both been down by around one-third on the comparable 
periods in 2019 (number of clients by 34% and number of visits by 32%). 
There were an estimated 3,590 people who injected opiate and crack across the nine local 
authorities in 2010/11 (the most recent estimates available). Using this as an estimate of the 
population size and the average number of needles provided to those using psychoactive drugs, NSP 
coverage for this group was estimated. The number of needles distributed per person injecting 
psychoactive drugs has halved, with the estimated coverage having declined from 14 needles per-
week during 4-week period ending 15th March 2020 to 7 needles per-week by mid-April, and 
coverage has remained at that level since then. 
Discussion 
The marked changes in the utilisation of NSP reported here are a concern. Caution is needed, as the 
impact of the COVID-19 restrictions on the levels of drug use and routes of drug administration 
remain unclear; however, any reductions in injecting drug use are unlikely to explain such a 
substantial decline. Our findings indicate that NSP coverage may have halved in an area where 
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monitoring was enhanced to provide timely data to inform action to mitigate negative impacts from 
the COVID-19 restrictions. Most areas of England, and many locations elsewhere globally, have more 
limited or minimal NSP monitoring. The falls in coverage might be greater in those areas without 
timely monitoring, and reduced provision has been reported in the USA (Bartholomew, et al., 2020) 
where NSP provision is less extensive than in the UK.  
Our analysis is based on enhanced data collation by an established monitoring system. IMS is well 
establish and covers all NSP sites in the region, with data quality assurance in place; however, data 
had not previously been collated and reported on a weekly basis. Some of the services could provide 
this data easily, while for others this was not the case. Where the underlying data recording does not 
take place in real-time, it is possible activity might be recorded in a different week to that in which it 
took place. We used mean values for four-weekly periods to minimise the possible impact of this, 
and to allow for public holidays (of which there were four in four different weeks during the period 
considered) which may cause peaks and troughs in service use. A second limitation is that the most 
recent estimate of the size of the psychoactive drug injecting population is 10-years old, and is only 
for the injection of heroin and crack. However, the overall size of the heroin and crack using 
population has changed little since then (Hay, Rael dos Santos, Reed, & Hope, 2019). Heroin and 
crack are by far the most commonly injected psychoactive drugs in the area, though other 
psychoactive drugs are injected. The estimate of the population sized used is thus probably a 
conservative one, and therefore may result in overestimation of coverage. 
Unless there has been a very marked and sudden decline in the injection of heroin and crack-
cocaine, the halving of NSP coverage probably indicates a rise in the re-use of injecting equipment. 
Thus, there is likely to have been an increase in the sharing of needle and syringes and so harm. As a 
consequence, the potential for outbreaks of HIV and HCV is now greatly elevated. The detection of 
such outbreaks would be unlikely as testing activity for HIV and HCV in the UK, as elsewhere, has 
been substantially reduced due to social distancing and the focus on testing for COVID-19 
(Bartholomew, et al., 2020; DHSC & PHE, 2020). A more immediate impact of any increased risk may 
be seen in injection related SSTIs. Monitoring of care seeking and admissions for SSTIs could be used 
as an indicator for any changes in risk and harm. 
As social distancing measures are likely to remain in place for some time, albeit modified, further 
action is required to ensure that those who need sterile needles and syringes can easily access these. 
Improved awareness of the continuation of the existing NSP provision and improvements to access 
are part of this. As the restrictions are lifted access to services should improve, but even with 
modified social distancing measures (e.g. a reduction from 2 metres to 1 metre) delivery of these will 
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pose challenges. Therefore, other approaches, such as, home delivery, provision by post, peer 
supported distribution, and vending machines need to be considered to improve equipment 
availability. Vending machines may be challenging to get in place quickly because of their sourcing 
and installation, but the other approaches could be implemented in a shorter time frame. Home 
delivery and peer distributions schemes already exist in some areas (NHS-SMPA, 2020) and have 
been expanded, but they require careful management to maintain social distancing. There are 
already direct postal sales of injecting equipment to some people who inject IPEDs (Exchange 
Supplies, 2020b). By utilising existing postal and courier services, establishing free postal NSP 
provision to all people who inject drugs could be achieved relatively quickly whilst maintaining social 
distancing, and such a service has been just set up in the UK (Exchange Supplies, 2020a). 
The decline in NSP utilisation could reflect changes in drug use practice. Those using IPEDs may have 
moved to oral drugs or rescheduled their cycles of use; though the decline for this group might 
reflect a move to online purchasing of needles. For those who inject psychoactive drugs, it is as yet 
unclear if there has been a decline in injecting, for example, due to people switching to use of oral 
drugs or abstaining. The decline in NSP use is marked and will, in part at least, reflect decreased 
utilisation rather than need, and so increased reuse of equipment. The decline requires further 
investigation to better understand its impacts on risk and harms and measures to improve coverage, 
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